These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Guo D; Kassiri Z; Basu R; Chow FL; Kandalam V; Damilano F; Liang W; Izumo S; Hirsch E; Penninger JM; Backx PH; Oudit GY Circ Res; 2010 Nov; 107(10):1275-89. PubMed ID: 20847309 [TBL] [Abstract][Full Text] [Related]
27. Subcellular remodeling as a viable target for the treatment of congestive heart failure. Dhalla NS; Dent MR; Tappia PS; Sethi R; Barta J; Goyal RK J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):31-45. PubMed ID: 16703218 [TBL] [Abstract][Full Text] [Related]
28. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Sabbah HN Heart Fail Rev; 2004 Apr; 9(2):91-7. PubMed ID: 15516856 [TBL] [Abstract][Full Text] [Related]
31. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Oie E; Bjørnerheim R; Clausen OP; Attramadal H Am J Physiol Heart Circ Physiol; 2000 Jun; 278(6):H2115-23. PubMed ID: 10843911 [TBL] [Abstract][Full Text] [Related]
32. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Hanna A; Frangogiannis NG Cardiovasc Drugs Ther; 2020 Dec; 34(6):849-863. PubMed ID: 32902739 [TBL] [Abstract][Full Text] [Related]
33. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Kobayashi N; Horinaka S; Mita S; Nakano S; Honda T; Yoshida K; Kobayashi T; Matsuoka H Cardiovasc Res; 2002 Sep; 55(4):757-67. PubMed ID: 12176125 [TBL] [Abstract][Full Text] [Related]
35. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Schram K; Sweeney G Trends Cardiovasc Med; 2008 Aug; 18(6):199-205. PubMed ID: 19185809 [TBL] [Abstract][Full Text] [Related]
36. Cardiac βarrestin2 Improves Contractility and Adverse Remodeling in Heart Failure, But Is Underexpressed in Humans. McCrink KA; Maning J; Vu A; Jafferjee M; Marrero C; Brill A; Bathgate-Siryk A; Dabul S; Koch WJ; Lymperopoulos A J Am Coll Cardiol; 2017 Dec; 70(23):2948-2949. PubMed ID: 29216991 [No Abstract] [Full Text] [Related]
37. Integrin expression during reverse remodeling in the myocardium of heart failure patients. Dullens HF; Schipper ME; van Kuik J; Sohns W; Scheenstra M; van Wichen DF; Van Oosterhout MF; de Jonge N; de Weger RA Cardiovasc Pathol; 2012; 21(4):291-8. PubMed ID: 22100988 [TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Creemers EE; Pinto YM Cardiovasc Res; 2011 Feb; 89(2):265-72. PubMed ID: 20880837 [TBL] [Abstract][Full Text] [Related]
39. [Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure: Part I]. Sirico D; Salzano A; Celentani D; Arcopinto M; Marra AM; Bobbio E; Russo A; Giallauria F; Vigorito C Monaldi Arch Chest Dis; 2014 Dec; 82(4):187-94. PubMed ID: 26562984 [TBL] [Abstract][Full Text] [Related]
40. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure]. Yang YJ; Zhang X; Zhu WL; Huang Y Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]